DNA X IncSONM
Price$4.14

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $59.4M-36.6% YoYTTM through 30 Sep 2025
Net Income -$8.5MTTM through 30 Jun 2026
Free Cash Flow -$14.7MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
EBITDA Margin-9.7%
Operating Margin-13.4%
Net Margin-14.4%

Returns

-189.2%ROA

Balance Sheet Health

Debt / Equity-1.12x
Current Ratio0.57x
Net Debt-$95Knet cash position
Cash & Equivalents$900K

Quality Metrics

Altman Z-Score-85.22
Piotroski F-Score2 / 9
FCF Margin-24.8%
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'23'24
FY2024: $58.3M
Diluted EPS-$8.26TTM
'22'23'24'25
FY2025: $-28.58

Dividend

No dividend

Capital Allocation

R&D Spend$15.2M
Capex Intensity0.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.